Objective: The population rate of alprazolam prescribing in Tasmania has been more than double that of national rates. Serious adverse events have been observed through co-administration of opioid medications with alprazolam. A two-fold intervention, comprising GP education coupled with changes to prescribing regulations, was designed with the intention to decrease inappropriate prescribing of alprazolam and thereby reduce adverse outcomes. The aim of this study was to assess the impact of the intervention on prescribing rates.
Method: We measured the number of alprazolam prescriptions for the years prior to and the year following the intervention. Health Insurance Commission data were utilized to enable comparison of subsidized prescription rates for alprazolam in Tasmania, and compared with national data. Participants were registered medical practitioners in Tasmania who were potential prescribers of alprazolam. The interventions were three GP Education Meetings during June 2007, one in each of the major regions of Tasmania, regarding evidence-based interventions for panic disorder. Changes to regulatory procedures to minimize co-prescription of alprazolam with opioids was implemented in September 2007.
Results: A reduction in alprazolam prescribing in Tasmania occurred after the interventions.
Conclusion: Education can be an effective strategy to influence prescribing behaviour of doctors. It is likely that this effect can be augmented by adoption of more stringent regulatory requirements.
WebberT. Professional Services Review. Report to the Professions 2007–08. Commonwealth of Australia, Canberra2009.
2.
MillerNGoldM. Abuse, addiction, tolerance, and dependence to benzodiazepines in medical and nonmedical populations. American Journal on Drug and Alcohol Abuse1991; 17: 27–37.
3.
BarkerMGreenwoodKJacksonMCroweS. Persistence of cognitive effects after withdrawal from long term benzodiazepine use: a meta-analysis. Archives of Clinical Neuropsychology2004; 19: 437–454.
4.
BaileyLWardMMusaM. Clinical pharmacokinetics of benzodiazepines. Journal of Clinical Pharmacology1994; 34: 804–811.
5.
Schedule of Pharmaceutical Benefits, August, 2006; Psycholeptics; Alpazolam.
6.
BarskyADelamaterBOravJ. Panic disorder patients and their medical care. Psychosomatics1999; 40: 50–56.
7.
FiferSMathiasSPatrickDMazonsonPLubeckDBueschingD. Untreated anxiety among adult primary care patients in a health maintenance organization. Archives of General Psychiatry1994; 51: 740–750.
8.
WeissmanMKlermanGMarkowitzJOuelletteR. Suicidal ideation and suicide attempts in panic disorder and attacks. New England Journal of Medicine1989; 321: 1209–1214.
9.
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphobia. Australia and New Zealand Clinical Practice Guidelines for the Treatment of Panic Disorder and Agoraphobia. Australian and New Zealand Journal of Psychiatry2003; 37: 641–656.
10.
BruceSVasileRGoismanRTzanisE. Are Benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?. American Journal of Psychiatry2003; 160: 1432–1438.
11.
TesarGRosenbaumJPollackM. Double-blind, placebo controlled comparison of clonazepam and alprazolam for panic disorder. Journal of Clinical Psychiatry1991; 52: 69–76.
12.
NoyesRBurrowsGReichJ. Diazepam versus alprazolam for the treatment of panic disorder. Journal of Clinical Psychiatry1996; 57: 349–355.
13.
DarkeSSwiftWHallWRossJ. Drug use, HIV risk-taking and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug and Alcohol Dependence1993; 34: 67–70.
14.
KerrTFairbairnNTyndallM. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug and Alcohol Dependence2007; 87: 39–45.
15.
FryCBrunoR. Recent trends in benzodiazepine use by injecting drug users in Victoria and Tasmania. Drug and Alcohol Review2002; 21: 363–367.
16.
RossJDarkeSHallW. Transitions between routes of benzodiazepine administration among heroin users in Sydney. Addiction1997; 92: 697–705.
17.
DobbinM. Association of benzodiazepine injection with the prescription of temazepam capsules. Drug and Alcohol Review2003; 22: 153–157.
18.
EddeyDPWestcottMJ. The needle and the damage done’: inter-arterial temazepam. Emergency Medicine2000; 12: 248–252.
19.
GilhoolyT. Reduction in use of temazepam is a factor in deaths related to overdose. British Medical Journal1997; 315: 1463–1464.
20.
BreenCDegenhardtLBrunoR. The effects of restricting publicly subsidized temazepam capsules on benzodiazepine use among injecting drug users in Australia. Medical Journal of Australia2004; 181: 300–304.
21.
BlackE, RoxburghA, DegenhardtL, Australian Drug Trends 2007: Findings from the Illicit Drug Reporting System (IDRS), Australian Drug Trends Series No. 1. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2008.
22.
DegenhardtLRoxburghAvan BeekI. The effects of the market withdrawal of temazepam gel capsules on benzodiazepine injecting in Sydney, Australia. Drug and Alcohol Review2008; 27: 145–151.
23.
de GraaffB, BrunoR. Tasmanian Drug Trends 2007: Findings from the Illicit Drug Reporting System (IDRS), Australian Drug Trends Series No. 5. Sydney: National Drug and Alcohol Research Centre, University of New South Wales,. 2008.
24.
GallowayJ. New Restrictions on the Prescribing of Alprazolam. Information Circular for Pharmacists in Tasmania, No. 42. Department of Health and Human Services, Tasmania2007.
25.
CharlesJBrittHValentiL. The independent effect of age of general practitioner on clinical practice. Medical Journal of Australia2006; 185: 105–109.
26.
SchectmanJKanwalNSchrothWElinskyE. The effect of an education and feedback intervention on group-model and network model health maintenance organization and physician prescribing behaviour. Medical Care1995; 33: 139–144.
27.
CockburnJPitS. Prescribing behaviour in clinical practice: patients’ expectations and doctors’ perception of patients’ expectations – a questionnaire study. British Medical Journal1997; 315: 520–523.
28.
GrecoPEisenbergJ. Changing physicians’ practices. New England Journal of Medicine1993; 329: 1271–1274.
29.
DavisDThompsonMOxmanAHaynesR. Changing physician performance. A systematic review of the effect of CME strategies. Journal of the American Medical Association1995; 274: 700–705.
30.
GrolR. Personal paper: Beliefs and evidence in changing clinical practice. British Medical Journal1997; 315: 418–421.
31.
SondergaardJHansenDAarslevPMunckA. A multifaceted intervention according to the Audit Project Odense method improved secondary prevention of ischaemic heart disease: a randomised controlled trial. Family Practice2006; 23: 198–202.
